Free Research Preview. DrugChatter may produce inaccurate information.
Save time and get answers to complex questions with AI chat
When will latisse patent expire?What excipients are combined with ruxolitinib in apotex's medication?Can wine consumption affect lipitor's cholesterol lowering ability?Are there specific stretches to avoid while on lipitor?How does paclitaxel's binding to albumin change its pharmacokinetics?
See the DrugPatentWatch profile for lurbinectedin
Lurbinectedin is approved for platinum-sensitive relapsed small cell lung cancer, not ovarian cancer. It is an alkylating agent that binds DNA major groove, disrupts transcription, tumor microenvironment, and tumor-supporting macrophages. It works differently from taxanes, platinum agents, and PARP inhibitors. How does lurbinectedin compare with platinum-based regimens? Lurbinectedin shows a 35% objective response rate in platinum-sensitive small cell lung cancer patients who progressed after first-line therapy. The median progression-free survival is 4.3 months and median overall survival 9.3 months. [1] In ovarian cancer studies, it has produced 18–30% response rates in platinum-sensitive cases and 0–15% in platinum-resistant cases. Those figures liegen unterhalb der response rates seen with platinum re-challenge itself, which usually exceeds 40%.
Other Questions About Lurbinectedin :